Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specified Drug Use Surveillance of Zafatek (trelagliptin) 25 mg in Type 2 Diabetes Mellitus With Severe Renal Impairment or End-Stage Renal Failure
jRCT1080225091Completed
- Sponsor
- Takeda
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trelagliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Primary endpoint: Long-term safety of trelagliptin 25 mg. Started Feb 2020; status: completed.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080225091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225091.